NVS Novartis AG Stock Quote

NVS [NYSE]

Healthcare | Drug Manufacturers - General | Switzerland

Index	-	P/E	8.45	EPS (ttm)	10.73	Insider Own	9.30%	Shs Outstand	2.23B	Perf Week	3.30%
Market Cap	211.55B	Forward P/E	13.32	EPS next Y	6.81	Insider Trans	0.00%	Shs Float	2.13B	Perf Month	1.68%
Income	24.18B	PEG	1.76	EPS next Q	1.52	Inst Own	9.50%	Short Float	0.30%	Perf Quarter	5.69%
Sales	53.00B	P/S	3.99	EPS this Y	202.30%	Inst Trans	-1.74%	Short Ratio	2.43	Perf Half Y	11.08%
Book/sh	27.66	P/B	3.28	EPS next Y	9.33%	ROA	19.30%	Target Price	104.40	Perf Year	3.06%
Cash/sh	8.07	P/C	11.24	EPS next 5Y	4.80%	ROE	40.30%	52W Range	79.09 - 95.17	Perf YTD	3.70%
Dividend	3.33	P/FCF	37.15	EPS past 5Y	30.60%	ROI	9.70%	52W High	-4.69%	Beta	0.51
Dividend %	3.67%	Quick Ratio	1.00	Sales past 5Y	1.40%	Gross Margin	71.00%	52W Low	14.69%	ATR	1.39
Employees	110000	Current Ratio	1.20	Sales Q/Q	0.90%	Oper. Margin	22.90%	RSI (14)	61.70	Volatility	1.03% 1.46%
Optionable	Yes	Debt/Eq	0.51	EPS Q/Q	9.30%	Profit Margin	45.60%	Rel Volume	1.50	Prev Close	89.42
Shortable	Yes	LT Debt/Eq	0.40	Earnings	Apr 26 BMO	Payout	29.60%	Avg Volume	2.63M	Price	90.71
Recom	2.00	SMA20	3.84%	SMA50	3.04%	SMA200	5.13%	Volume	3,911,775	Change	1.44%

May-09-22

Downgrade

Wolfe Research

Outperform → Peer Perform

Jan-10-22

Resumed

Citigroup

Buy

Dec-14-21

Downgrade

Redburn

Buy → Neutral

Dec-06-21

Downgrade

Exane BNP Paribas

Outperform → Neutral

Dec-03-21

Downgrade

Bryan Garnier

Buy → Neutral

Sep-20-21

Downgrade

Deutsche Bank

Hold → Sell

Mar-22-21

Initiated

Bernstein

Mkt Perform

Mar-10-21

Downgrade

Argus

Buy → Hold

Feb-01-21

Downgrade

Cowen

Outperform → Market Perform

$110 → $105

Jan-15-21

Initiated

Deutsche Bank

Buy

Sep-29-20

Initiated

Berenberg

Buy

Sep-10-20

Upgrade

UBS

Neutral → Buy

Sep-01-20

Upgrade

Morgan Stanley

Equal-Weight → Overweight

Jun-15-20

Upgrade

Citigroup

Neutral → Buy

Mar-10-20

Upgrade

Morgan Stanley

Underweight → Equal-Weight

Feb-25-20

Downgrade

Guggenheim

Buy → Neutral

Apr-25-19

Upgrade

Liberum

Hold → Buy

Apr-25-19

Upgrade

Guggenheim

Neutral → Buy

Apr-10-19

Downgrade

Morgan Stanley

Equal-Weight → Underweight

Jan-02-19

Downgrade

JP Morgan

Neutral → Underweight

May-24-22 04:49AM	Stock markets: Mining and oil shares drive dividend payouts to first quarter record Yahoo Finance UK
May-23-22 11:46AM	Novartis (NVS) Cosentyx Gets Positive CHMP Opinion for JIA Zacks
May-20-22 08:34AM	Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions GlobeNewswire
02:00AM	CORRECTED-Cancer coalition aims to boost access to medicines in poorer countries Reuters
May-19-22 12:34PM	Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition Zacks
May-18-22 10:37AM	Should You Buy This High-Yielding Big Pharma Stock? Motley Fool
May-17-22 05:59PM	Seattle's Max Foundation launches global push to serve cancer patients American City Business Journals
May-13-22 07:15AM	3 Undervalued Stocks to Buy Before You Sell in May and Go Away InvestorPlace
May-12-22 04:04PM	Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis Investor's Business Daily
10:28AM	Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer GlobeNewswire
May-11-22 11:15AM	Got $5,000? Buy and Hold These 3 Dividend Growth Stocks for the Long Haul Motley Fool
May-06-22 11:02AM	Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss Zacks
May-05-22 01:37PM	Novartis suspends delivery of cancer treatment as it address potential production issues MarketWatch
12:30PM	Novartis suspends two cancer therapies over quality concerns Reuters
11:45AM	Ionis (IONS) Q1 Earnings & Sales Beat Estimates, Stock Rises Zacks
May-04-22 03:00AM	New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients GlobeNewswire
May-03-22 11:53AM	Incyte's (INCY) Q1 Earnings and Revenues Fall Shy of Estimates Zacks
07:00AM	Dianthus, a new $100M startup, aims to make autoimmune treatments easier American City Business Journals
May-02-22 10:45AM	Novartis Is Looking for Deals. Are These 3 Biotechs on Its List? Motley Fool
Apr-29-22 12:33PM	Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View Zacks
10:32AM	Pharma Stock Roundup: Q1 Earnings of LLY, MRK & NVS, FDA Updates for AZN & PFE Zacks
Apr-27-22 12:17PM	Incyte (INCY) to Report Q1 Earnings: What's in the Cards? Zacks
09:48AM	Why Big Tech has struggled in the health-care space, according to Intel chair Yahoo Finance
09:45AM	Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial Benzinga
06:00AM	Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study GlobeNewswire
05:59AM	Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data Benzinga
Apr-26-22 05:30PM	Novartis (NVS) Q1 2022 Earnings Call Transcript Motley Fool
04:08PM	Here's The Surprising Source Of Novartis' First-Quarter Sales Growth Investor's Business Daily
10:15AM	Novartis (NVS) Beats on Q1 Earnings, Sandoz Posts Growth Zacks
06:49AM	Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook Benzinga
04:36AM	Novartis Earnings Get a Boost From Sales of Its Key Drugs Barrons.com
03:15AM	Novartis CEO on First-Quarter Earnings, Drugs Pipeline Bloomberg
01:24AM	Novartis income edges higher on strong Sandoz, Entresto Reuters
01:00AM	Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook GlobeNewswire
Apr-25-22 01:16PM	Novartis (NVS) Gets Positive CHMP Opinion on Lung Cancer Drug Zacks
Apr-22-22 12:00PM	EMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer Setting Benzinga
09:27AM	Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer GlobeNewswire
Apr-20-22 10:19AM	KemPharm (KMPH) Starts Early-Stage Cardiovascular Safety Study Zacks
Apr-18-22 06:04AM	3 Fantastic Biotech Stocks to Buy in April Motley Fool
Apr-14-22 01:15AM	Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio GlobeNewswire
Apr-13-22 10:25AM	BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study Zacks
09:09AM	10 Biotech Stocks to Buy Today According to Ken Fisher Insider Monkey
Apr-12-22 10:23AM	BeiGene (BGNE) Brukinsa Superior to Imbruvica in Leukemia Study Zacks
03:18AM	Novartis to cut thousands of jobs in global revamp - paper Reuters
Apr-08-22 09:28AM	Pharma Stock Roundup: PFE to Buy RSV Drugmaker, FDA Updates for NVS, MRK and RHHBY Zacks
Apr-07-22 02:55PM	Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids Zacks
12:05PM	Novartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer Zacks
10:06AM	Novartis CEO Continues His Shake-Up, Says It Will Save More Than $1 Billion Annually Barrons.com
08:53AM	Novartis CEO Continues His Shake-Up, Says It Will Save More Than $1 Billion Annually Barrons.com
Apr-06-22 11:58AM	Novartis (NVS) Gets FDA Nod for Vijoice in Rare Disorder Zacks
09:28AM	Novartis' Breast Cancer PI3K Drug, Scores FDA Approval For Ultra-Rare Indication Benzinga
01:15AM	Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR) GlobeNewswire
Apr-05-22 08:29PM	FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS) GlobeNewswire
03:06PM	Durham facility gets green light to produce 'world's most expensive drug' American City Business Journals
01:15AM	Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility GlobeNewswire
Apr-04-22 11:00AM	Accenture (ACN) Joins Health Data Collaborative, AI4BetterHearts Zacks
10:36AM	Novartiss Restructuring Expected to Lead to $1 Billion in Cost Savings The Wall Street Journal
05:27AM	Novartis shakes up structure to strengthen US business Financial Times
01:19AM	Novartis to save at least $1 billion by 2024 thanks to simplified structure Reuters
01:00AM	Novartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity GlobeNewswire
Apr-02-22 06:43PM	10 Biotech Stocks to Buy According to Billionaire David E. Shaw Insider Monkey
Apr-01-22 09:09AM	Pharma Stock Roundup: FDA Nod for 2nd COVID Booster, New Approvals for AZN, GSK, NVS Zacks
08:48AM	Novartis (NVS) Beovu Gets Label Expansion for DME in EU Zacks
Mar-29-22 11:23AM	CVS Health Stock Gets Downgraded. This Analyst Sees Multiple Risks. Barrons.com
06:56AM	The Zacks Analyst Blog Highlights Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences Zacks
Mar-28-22 02:06PM	Top Stock Reports for Visa, Novartis & Deere Zacks
01:27PM	Novartis (NVS) Gets Positive CHMP Opinion for Jakafi, Kymriah Zacks
Mar-25-22 01:43PM	Novartis Receives Positive CHMP Opinion For Kymriah In Follicular Lymphoma, Jakavi In GvHD Benzinga
08:09AM	Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease GlobeNewswire
08:03AM	Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe GlobeNewswire
06:35AM	The Zacks Analyst Blog Highlights Novartis, Merck and Pfizer Zacks
Mar-24-22 01:39PM	Novartis' (NVS) Pluvicto Gets FDA Nod for Advanced Prostate Cancer Zacks
10:14AM	Pharma Stock Roundup: NVS, MRK Get FDA Nod, PFE Ulcerative Colitis Study Succeeds Zacks
08:54AM	FDA Approves Novartis' Pluvicto As First Targeted Radioligand Therapy For Prostate Cancer Benzinga
Mar-23-22 05:15PM	UPDATE 1-U.S. FDA approves Novartis therapy for prostate cancer Reuters
04:19PM	Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer GlobeNewswire
04:19PM	Novartis Pluvicto approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer GlobeNewswire
Mar-22-22 03:34AM	Novartis suspends some business activities in Russia Reuters
Mar-19-22 06:05AM	Pfizer and Novartis Are Betting On This Under-the-Radar Biotech. Should You? Motley Fool
Mar-18-22 09:10AM	Incyte's (INCY) Going Gets Tough Due to Pipeline Setbacks Zacks
Mar-17-22 10:45AM	Top Pharmaceutical Stocks for Q2 2022 Investopedia
Mar-16-22 10:23PM	Novartis and Roche Have Expensive Drugs That Scare Away Competitors TheStreet.com
12:16PM	These Drugs Are Money Spinners for Novartis, AstraZeneca and Roche TheStreet.com
Mar-15-22 11:37AM	Incyte (INCY) Label Expansion for Ruxolitinib Cream Delayed Zacks
11:07AM	2 Top Stocks to Buy in March and Hold Forever Motley Fool
Mar-14-22 12:57PM	Novartis's Data Reinforces Age-Appropriate Development With Zolgensma Gene Therapy Study Benzinga
12:18PM	Novartis (NVS) Announces Data on Zolgensma, Acquires Coalesce Zacks
06:05AM	3 No-Brainer Stocks to Buy With $1,000 Right Now Motley Fool
02:15AM	Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce GlobeNewswire
Mar-13-22 07:00PM	Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection GlobeNewswire
Mar-10-22 12:27PM	The Zacks Analyst Blog Highlights Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences Zacks
Mar-09-22 12:54PM	Biotech Stock Roundup: OCGN Down on Update, VYGR Surges on Deal & Other Updates Zacks
12:35PM	Voyager (VYGR) Gains on Deal With Novartis for Gene Therapies Zacks
Mar-08-22 02:20PM	Voyager inks gene therapy deal with Novartis worth up to $1.8B American City Business Journals
08:30AM	Voyager, Novartis sign deal worth up to $1.7 billion MarketWatch
06:27AM	Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs Benzinga
06:16AM	Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results GlobeNewswire
Mar-04-22 09:19AM	Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting GlobeNewswire
Feb-23-22 12:02PM	The Zacks Analyst Blog Highlights NVIDIA, Novartis AG, NextEra Energy, The Goldman Sachs Group and Amgen Zacks
Feb-22-22 12:54PM	Top Stock Reports for NVIDIA, Novartis & NextEra Energy Zacks

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience